OUTLOOK

KIDNEY CANCER
15 September 2016 / Vol 537 / Issue No 7620

K
OUTLOOK 15 September 2016
Supplement to Nature
Research journals
idney cancer has long flown under the radar despite
KIDNEY CANCER being one of the top-ten cancer killers — it lacks the CONTENTS
research spotlight and public awareness that can help
to drive new discoveries for other cancers. The disease remains
S98 BIOLOGY
hard to detect, difficult to treat and poorly understood. The silent disease
But that is beginning to change. Researchers are digging into A graphical guide to kidney cancer
some of the mysteries surrounding the disease — such as why
Fixing a
obesity seems to be a risk factor, but also offers some protection S100 OBESITY
Produced with support from:

fouled filter

against its worst effects (see page S100), and why alcohol The fat advantage
Cover art: Tommy Parker
Is obesity really protective?
consumption, which predisposes people to many cancers,
Editorial seems to help defend against kidney cancer (S103).
Herb Brody
S103 ALCOHOL
Michelle Grayson Genetics and the hunt for biochemical markers are bringing Fortifying spirits
Richard Hodson researchers closer to understanding the causes of kidney Could a drink a day protect against
Brian Owens cancer, but some say that scientists need to look beyond the kidney cancer?
Jenny Rooke
genome, and consider environmental and lifestyle factors to S105 PERSPECTIVE
Art & Design
Mohamed Ashour
truly understand why people develop the disease (S105). Beyond the genome
Kate Duncan For years, people with kidney cancer had few options for Integrating epidemiological data will
Wesley Fernandes treatment beyond surgery, and survival times rarely exceeded increase understanding of the disease,
Lucy Reading-Ikkanda one year. But in the past decade there has been an explosion of say John Leppert and Chirag Patel
Production therapies, which target pathways such as the genes and proteins
Karl Smart S106 TARGETED THERAPY
Ian Pope that control tumour growth and the creation of blood vessels. An elusive cancer target
Matthew Carey These drugs are effective against advanced cancer, but they fail Therapies for advanced disease don’t
Sponsorship to stop the tumours returning (S106). Another set of drugs, work for cancers caught early
Yvette Smith which turns the body’s immune system against the tumours, is
Janice Stevenson S109 IMMUNOTHERAPY
also offering hope (S109).
Marketing Controlled attack
Nicole Jackson Even with all this progress, there are many unanswered The potential of checkpoint inhibitors
Project Manager questions and unexplored avenues of research. Researchers still
Anastasia Panoutsou need to find new ways to predict and detect the disease, reduce S111 PERSPECTIVE
Art Director the harmful side effects of drugs and make treatments last What next for treatment?
Kelly Buckheit Krause longer (S111). Only then will this disease be beaten. Robert Motzer explains what needs to
Publisher be done to make progress
We are pleased to acknowledge the support of Eisai Inc.
Richard Hughes
in producing this Outlook. As always, Nature has sole
Editorial Director,
Partnership Media responsibility for all editorial content.
Stephen Pincock RELATED ARTICLES
Editor-in-Chief Brian Owens S112 Circulating biomarkers and outcome
Philip Campbell Contributing editor from a randomised phase II trial of
sunitinib vs everolimus for patients
with metastatic renal cell carcinoma
Nature Outlooks are sponsored supplements that aim to stimulate All featured articles will be freely available for 6 months. M. H. Voss et al.
interest and debate around a subject of interest to the sponsor, SUBSCRIPTIONS AND CUSTOMER SERVICES
while satisfying the editorial values of Nature and our readers’ Site licences (www.nature.com/libraries/site_licences): Americas, S120 Final results from the large sunitinib
expectations. The boundaries of sponsor involvement are clearly
delineated in the Nature Outlook Editorial guidelines available at
institutions@natureny.com; Asia-Pacific, http://nature.asia/ global expanded-access trial in
jp-contact; Australia/New Zealand, nature@macmillan.com.au;
go.nature.com/e4dwzw Europe/ROW, institutions@nature.com; India, npgindia@nature. metastatic renal cell carcinoma
CITING THE OUTLOOK com. Personal subscriptions: UK/Europe/ROW, subscriptions@ M. E. Gore et al.
Cite as a supplement to Nature, for example, Nature Vol. XXX, nature.com; USA/Canada/Latin America, subscriptions@
No. XXXX Suppl., Sxx–Sxx (2016). us.nature.com; Japan, http://nature.asia/jp-contact; China, http://
VISIT THE OUTLOOK ONLINE nature.asia/china-subscribe; Korea, www.natureasia.com/ko-kr/ S128 Renal cell carcinoma escapes
The Nature Outlook Kidney Cancer supplement can be found at subscribe. death by p53 depletion through
http://www.nature.com/nature/outlook/kidney-cancer CUSTOMER SERVICES transglutaminase 2-chaperoned
It features all newly commissioned content as well as a selection of Feedback@nature.com
relevant previously published material. Copyright © 2016 Macmillan Publishers Ltd. All rights reserved. autophagy
J. H. Kang et al.

1 5 S E P T E M B E R 2 0 1 6 | VO L 5 3 7 | NAT U R E | S 9 7
©
2
0
1
6
M
a
c
m
i
l
l
a
n
P
u
b
l
i
s
h
e
r
s
L
i
m
i
t
e
d
,
p
a
r
t
o
f
S
p
r
i
n
g
e
r
N
a
t
u
r
e
.
A
l
l
r
i
g
h
t
s
r
e
s
e
r
v
e
d
.